Table 1.
Clinical characteristics of the patients
| Variable | n = 24 |
|---|---|
| Age | 72.5 (54–88) |
| Sex (female/male) | 6/18 |
| Dose (8/12), mg | 8/16 |
| BCLC staging (B/C) | 7/17 |
| TNM staging (3/4a/4b) | 7/4/13 |
| T (0/1/2/3/4) | 2/2/6/11/3 |
| M (0/1) | 12/12 |
| N (0/1) | 17/7 |
| Main tumor size, mm | 30 (0–135) |
| MVI (Vp2/Vp3/Vv) | 1/1/0 |
| AFP, ng/mL | 10.3 (0.5–142,400) |
| DCP, mAU/mL | 182.5 (13–37,535) |
| ALBI grade(G1/G2) | 9/15 |
| Platelet, ×10^4/μL | 15.7 (5.7–144) |
| PT, % | 85.5 (68–110) |
| Albumin, g/dL | 3.6 (2.9–4.8) |
| Total bilirubin, mg/dL | 0.7 (0.4–1.7) |
| AST, IU/L | 32 (16–163) |
| ALT, IU/L | 20.5 (6–91) |
| γGTP, IU/L | 50.5 (11–183) |
| Etiology (HBV/HCV/NBNC) | 5/11/8 |
BCLC Barcelona Clinic Liver Cancer, TNM Tumor, Node, Metastasis, MVI macroscopic portal vein invasion, AFP alpha-fetoprotein, DCP des-gamma-carboxy pro-thrombin, ALBI albumin-bilirubin, PT prothrombin time, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-B non-C